Cangene Announces Extension of VIGIV Biodefence Contract with U.S. Government

September 3, 2013

Cangene Corporation (Cangene) announced today that the scope of work under its contract with the Centers for Disease Control and Prevention (CDC) for the supply of Vaccinia Immune Globulin Intravenous (VIGIV) into the U.S. Strategic National Stockpile has been expanded. The contract, which relates to United States Government biodefence programs, has been extended by 18 months and has also been modified to include three additional option periods that extend through 2017.

Click here for the article.

Share This Story